Azacitidine Injection Shortage Status Update
Areazine synthesizes this FDA drug-shortage notice directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.
Azacitidine Injection, an oncology medication, is currently listed in the FDA database, with both manufacturers reporting availability as of the latest update.
What this FDA drug-shortage notice tells you, and what most readers miss
This notice was issued by FDA on April 8, 2026 and geographically references United States. Its severity classification of "low" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - Drug Shortages - determines the regulatory framework behind it, which shapes what mitigations (alternative therapies, allocation timelines, manufacturer guidance) are available and which agency holds oversight.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.
Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are drug-shortage, fda, medication, Azacitidine.
What's in Shortage
The drug in shortage is Azacitidine Injection. Its generic name is Azacitidine Injection, with brand names AZACITIDINE and VIDAZA. The dosage form is Injection, and it falls under the therapeutic category of Oncology. The current status is listed as Current in the FDA database, with the initial posting date of 12/18/2020 and last updated on 04/02/2026.
Which Manufacturers Are Affected
- Fresenius Kabi USA, LLC: Availability is reported as Available. Related information includes 4 & 7 month expiry available on request, and patients should check wholesalers for inventory. The presentation is Azacitidine, Injection, 100 mg/30 mL (NDC 63323-771-39). Contact information: 1-888-386-1300.
- Bristol Myers Squibb Co.: Availability is reported as Available. The presentation is Vidaza, Injection, 100 mg (NDC 59572-102-01). Contact information: 1-888-423-5436.
Why There's a Shortage
No specific reason was provided for this shortage.
What Patients Should Do
Patients who depend on this medication should talk to their pharmacist or healthcare provider to check on availability and discuss options. They can also contact the manufacturers directly for more information. Please remember that patients should always consult their healthcare provider for any concerns and not make changes to their treatment without professional guidance.
Source
This information is from the FDA Drug Shortages Database.
Original source: FDA Official Notice ↗
Related Drug Shortages
All Drug Shortages →Nationwide notices with similar length or severity timing 8
Two Areazine-derived peer sets for this FDA drug-shortage notice: nearest notices by body length and by same severity near the same agency date. Peers come from other categories so they are not the same-feed Related list above.
Similar body length
Nearest notices by article body length (1,438 characters here).
Similar severity timing
Same severity (low) notices issued closest in time to April 8, 2026.
Frequently Asked Questions
Common questions about this FDA drug-shortage notice.